

# GLECAPREVIR/PIBRENTASVIR ASSOCIATION FOR CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS IN HEALTH

M.D. GIL-SIERRA<sup>1</sup>, E. RIOS-SANCHEZ<sup>1</sup>, F. TELLEZ-PEREZ<sup>2</sup>, M.D.P. BRICEÑO-CASADO<sup>1</sup>, S. FENIX-CABALLERO<sup>1</sup>, C. MARTINEZ-DIAZ<sup>1</sup>, J. DIAZ-NAVARRO<sup>1</sup>, C. PALOMO-PALOMO<sup>1</sup>, E.J. ALEGRE-DEL REY<sup>1</sup>, M. CAMEAN-CASTILLO<sup>1</sup>, J.M. BORRERO-RUBIO<sup>1</sup>. <sup>1</sup>HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN. <sup>2</sup>HOSPITAL UNIVERSITARIO DE PUERTO REAL, INTERNAL MEDICINE SERVICE, PUERTO REAL, SPAIN.

J05 - Antivirals for systemic use

5PSQ-039

## BACKGROUND

**European Medicines Agency** authorised glecaprevir/pibrentasvir combination for treatment of hepatitis C virus(HCV) infection in July 2017. Treating hospital patients and institutionalized population is essential to reduce transmission of virus infection.


## PURPOSE

To evaluate **effectiveness** and **tolerance** of HCV patients treated with glecaprevir/pibrentasvir in hospital and penitentiary centers.

## MATERIAL AND METHODS

**Descriptive** and **retrospective** study of HCV patients receiving glecaprevir/pibrentasvir from November 2017 to October 2018. Hospital and prison patients were selected.


- DATA**
- Age
  - Gender
  - Patient type → (naïve/pretreated)
  - Hepatic fibrosis stage
  - HCV genotype (G)
  - Medical departments
  - Treatment duration
  - Loss of follow-up after ending treatment
  - Diagnosed and treated by hospital
  - Information included in electronic medical history
  - withdrawal treatments and HCV recurrence




## RESULTS

- **Patients:** 114.
- **Gender:** 101 (88.6%) males.
- **Mean age:** 51.7 (29-73) years.
- **Patient type:** 96 (84.2%) naïve.
- **Glecaprevir/pibrentasvir prescriptions:** 30 (26.3%) internal medicine-infectious department, 33 (29%) digestive and 51 (44.7%) penitentiary centers
- **Duration of treatment:** 8 weeks for 104 (91.4%) patients and 12 weeks for 10 (8.6%, all cirrhotic).
- **Loss of follow-up:** 6 (5.2%, all digestive) patients
- **Withdrawal treatments:** 2 (1.7%, all prison) patients
- **HCV recurrence:** 1 (0.9%) interferon-ribavirin-pretreated patient


Hepatic fibrosis stage



HCV genotype distribution



Reacciones Adversas



	EOT	SVR12
Effectiveness	111 (97.5%)	109 (96.1%)

## CONCLUSION

1. **High rates of EOT and SVR12** in real-world patients were observed.
2. **Few patients reported RA** and all associated **withdrawal treatments** were recorded in population of penitentiary centers



<http://www.eahp.eu/24-5PSQ-039>